American Journal of Respiratory Cell and Molecular Biology. Vol. 27, pp. 306-313, 2002
© 2002 American Thoracic Society
DOI: 10.1165/rcmb.4850
Neuregulin-1 Activates the JAK-STAT Pathway and Regulates Lung Epithelial Cell Proliferation
Jinbo Liu and
Jeffrey A. Kern
Department of Internal Medicine, Pulmonary and Critical Care Division, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio
Address correspondence to: Jeffrey A. Kern, M.D., Department of Medicine, Pulmonary and Critical Care Division, University Hospital of Cleveland, Wearn 610, 11100 Euclid Avenue, Cleveland, OH 44106. E-mail: Jeffrey.Kern{at}UHHS.com
Neuregulin-1 (NRG-1) is part of a family of proteins whose members are structurally related to epidermal growth factor. NRG-1 induces cell proliferation through a high-affinity receptor complex composed of a heterodimer of human epidermal growth factor–like receptor (HER) 2 and 3. In this study, we show that NRG-1 activates the Janus kinases (JAK) and signal transducer and activator of transcription proteins (STAT). NRG-1 induced a rapid and transient increase in tyrosine phosphorylation of TYK2 and JAK3, but not JAK1 or JAK2, and induced STAT3 and STAT5 tyrosine phosphorylation. Upon phosphorylation, STAT3 translocated to the nucleus within 1 h. Activation of the JAK-STAT pathway was dependent on HER2/HER3 heterodimerization and was necessary for NRG-1–induced proliferation. Inhibition of HER2's ability to dimerize using the HER2-specific antibody 2C4 completely blocked NRG-1–induced JAK3, TYK2, STAT3, and STAT5 tyrosine phosphorylation. Blocking the JAK-STAT pathway with a specific JAK-STAT pathway inhibitor, AG490, inhibited NRG-1–induced JAK and STAT phosphorylation and cell proliferation. These data suggest that NRG-1 activates the JAK-STAT signal transduction pathway through its high-affinity receptor, the HER2/HER3 heterodimer. This pathway plays an important role in NRG-1–stimulated proliferation of pulmonary epithelial cells.
Abbreviations: human anti-HER2 antibody, 2C4 • Dulbecco's modified Eagle's medium, DMEM • dimethyl sulfoxide, DMSO • epidermal growth factor, EGF • extracellular-regulated kinase, ERK • fetal calf serum, FCS • human EGF-like receptor, HER • Janus kinase, JAK • neu differentiation factor, NDF • neureglin-1, NRG-1 • phosphate-buffered saline, PBS • platelet-derived growth factor receptor, PDGFR • phosphoinositide 3-kinase, PI3K • receptor tyrosine kinase, RTK • signal transducer and activator of transcription protein, STAT • sodium dodecyl sulfate polyacrylamide gel electrophoresis, SDS-PAGE • transforming growth factor, TGF
This article has been cited by other articles:
|
|
|
|
 
J. Albanell, C. Montagut, E. T. Jones, L. Pronk, B. Mellado, J. Beech, P. Gascon, G. Zugmaier, M. Brewster, M. P. Saunders, et al.
A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors
Clin. Cancer Res.,
May 1, 2008;
14(9):
2726 - 2731.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Faress, D. E. Nethery, E. F. O. Kern, R. Eisenberg, F. J. Jacono, C. L. Allen, and J. A. Kern
Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2
J Appl Physiol,
December 1, 2007;
103(6):
2077 - 2083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Wu, H. Miao, and S. Khan
JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism
Am J Physiol Renal Physiol,
December 1, 2007;
293(6):
F1836 - F1846.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Arpino, C. Gutierrez, H. Weiss, M. Rimawi, S. Massarweh, L. Bharwani, S. De Placido, C. K. Osborne, and R. Schiff
Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy
J Natl Cancer Inst,
May 2, 2007;
99(9):
694 - 705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Nethery, S. Ghosh, S. C. Erzurum, and J. A. Kern
Inactivation of neuregulin-1 by nitration
Am J Physiol Lung Cell Mol Physiol,
January 1, 2007;
292(1):
L287 - L293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Lin, R. Lai, L. R. Chirieac, C. Li, V. A. Thomazy, I. Grammatikakis, G. Z. Rassidakis, W. Zhang, Y. Fujio, K. Kunisada, et al.
Constitutive Activation of JAK3/STAT3 in Colon Carcinoma Tumors and Cell Lines: Inhibition of JAK3/STAT3 Signaling Induces Apoptosis and Cell Cycle Arrest of Colon Carcinoma Cells
Am. J. Pathol.,
October 1, 2005;
167(4):
969 - 980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Nethery, B. B. Moore, G. Minowada, J. Carroll, J. A. Faress, and J. A. Kern
Expression of mutant human epidermal receptor 3 attenuates lung fibrosis and improves survival in mice
J Appl Physiol,
July 1, 2005;
99(1):
298 - 307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Imaizumi, M. Kumagai, K. Taima, T. Fujita, H. Yoshida, and K. Satoh
Involvement of retinoic acid-inducible gene-I in the IFN-{gamma}/STAT1 signalling pathway in BEAS-2B cells
Eur. Respir. J.,
June 1, 2005;
25(6):
1077 - 1083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B. Agus, M. S. Gordon, C. Taylor, R. B. Natale, B. Karlan, D. S. Mendelson, M. F. Press, D. E. Allison, M. X. Sliwkowski, G. Lieberman, et al.
Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer
J. Clin. Oncol.,
April 10, 2005;
23(11):
2534 - 2543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Ray and L. W. Enquist
Transcriptional Response of a Common Permissive Cell Type to Infection by Two Diverse Alphaherpesviruses
J. Virol.,
April 1, 2004;
78(7):
3489 - 3501.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Sithanandam, G. T. Smith, A. Masuda, T. Takahashi, L. M. Anderson, and L. W. Fornwald
Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway
Carcinogenesis,
October 1, 2003;
24(10):
1581 - 1592.
[Abstract]
[Full Text]
[PDF]
|
|
|
Copyright © 2002 American Thoracic Society.
|
|
|
